Drug Alcohol Depend. 2025 Jan 29;268:112586. doi: 10.1016/j.drugalcdep.2025.112586. Online ahead of print.
ABSTRACT
PURPOSE: To assess real-world access to buprenorphine treatment in Philadelphia and measure adoption of policies and practices that facilitate buprenorphine access.
METHODS: We used an audit (“secret shopper”) design to survey all programs providing longitudinal, outpatient buprenorphine in Philadelphia from 9/2022-1/2023 (n = 130). After validating eligibility, a research coordinator posing as a case manager called eligible programs to inquire about appointment availability and treatment policies. We used descriptive statistics to analyze the data and compared practices between primary and subspecialty treatment providers.
RESULTS: We reached 107 programs with audit calls (82 % response rate). 56 (52 %) were primary care offices and 51 (48 %) were specialty addiction providers. 96 (90 %) accepted new patients for buprenorphine treatment, and 83 (78 %) accepted insurance. Median time-to-appointment was 3 business days (range 0-120), and 42 % of visits were offered with a single call. Only 42 % of programs could confirm the possibility of a buprenorphine prescription at an initial visit. 48 % of programs could not provide information about requirements for counseling or behavioral health, and few could provide information about policies for patients with ongoing substance use. Specialty models were more likely than primary care programs to provide information about medication availability at the first visit but also were more likely to require counseling and abstinence.
CONCLUSIONS: Our study provides a simulation of real-world experiences accessing buprenorphine, revealing significant variability in treatment access and persistence of practice-level barriers to treatment. These findings can inform efforts to increase engagement and retention in treatment and better align care with evidence.
PMID:39899919 | DOI:10.1016/j.drugalcdep.2025.112586
